Abiraterone Acetate CAS: 154229-18-2

CAS NO: 154229-18-2
Abiraterone Acetate
Chemical Name: Abiraterone acetate
Molecular Formula: C26H33NO2
Formula Weight: 391.55
CAS No.: 154229-18-2
Description Review
Description

Abiraterone Acetate is a well-known drug used for the treatment of metastatic castration-resistant prostate cancer. It belongs to the class of drugs known as androgen synthesis inhibitors, which are used to inhibit the activity of the androgen hormone, that is responsible for the growth and spread of prostate cancer. Abiraterone Acetate CAS: 154229-18-2 is a medication that has been approved by the FDA for the treatment of prostate cancer in men who have already received hormone therapy.

Chemical name: (3β)-17-(Pyridin-3-yl)androsta-5,16-dien-3-yl acetate Molecular formula: C26H33NO2 Formula weight: 391.55 g/mol CAS No: 154229-18-2

Top ten keywords from Google:

  1. Abiraterone Acetate prostate cancer
  2. Abiraterone Acetate mechanism of action
  3. Abiraterone Acetate dosage
  4. Abiraterone Acetate cost
  5. Abiraterone Acetate side effects
  6. Abiraterone Acetate synthesis
  7. Abiraterone Acetate half-life
  8. Abiraterone Acetate mode of action
  9. Abiraterone Acetate and prednisone
  10. Abiraterone Acetate structure

Synonyms: Abiraterone; Abirateronum; CB-7598; Yonsa; Zytiga.

Health benefits of Abiraterone Acetate: Abiraterone Acetate is a hormone therapy drug that blocks the production of testosterone in the body, which can help reduce or slow the growth of prostate cancer cells. The drug has been shown to be effective in treating advanced prostate cancer, and can help improve the overall quality of life for patients, reducing pain and improving mobility.

Potential effects: Abiraterone Acetate works by blocking an enzyme called CYP17, which is responsible for the production of testosterone in the body. This helps to reduce the levels of testosterone in the body, which can help slow down the growth of prostate cancer cells. The drug has been shown to be effective in clinical trials, and has been approved by the FDA for use in the treatment of metastatic castration-resistant prostate cancer.

Product mechanism: Abiraterone Acetate works by inhibiting the activity of an enzyme called CYP17, which is involved in the synthesis of androgens - male hormones that play a key role in the development and growth of prostate cancer. By blocking this enzyme, Abiraterone Acetate effectively reduces the production of androgens, which can help slow down the growth and spread of prostate cancer cells.

Safety: Abiraterone Acetate is generally considered to be safe, although like all medications, it can cause side effects in some patients. These can include fatigue, joint pain, fluid retention, high blood pressure, and liver toxicity. Patients should talk to their doctor about any concerns or questions they may have about the safety of this medication.

Side effects: The most common side effects of Abiraterone Acetate include fatigue, joint pain, nausea, vomiting, fluid retention, high blood pressure, and liver toxicity. In rare cases, the drug can cause serious allergic reactions, including anaphylaxis or anaphylactoid reactions. Patients who experience any of these symptoms should seek medical attention immediately.

Dosing Information: Abiraterone Acetate is typically taken once a day, with or without food. The drug is available in tablet form, and the recommended dosage is usually 1000mg per day. Patients should follow their doctor's instructions carefully regarding the dosage, frequency, and duration of treatment.

Conclusion: Abiraterone Acetate is an important drug used in the treatment of metastatic castration-resistant prostate cancer. The drug has been shown to be effective in reducing pain, slowing down the growth of prostate cancer cells, and improving the quality of life for patients. While the drug has some potential side effects, it is generally well-tolerated by patients and is considered to be safe for use in the treatment of prostate cancer. Patients should talk to their doctor about any concerns or questions they may have about the use of Abiraterone Acetate, and should always follow their doctor's instructions carefully regarding dosage, frequency, and duration of treatment.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us